DCPH   $25.59  0.16% Market Closed

Deciphera Pharmaceuticals Inc
Last Events:

2023-08-09 Trend pattern changed from расширяющаяся формация to нисходящий клин.

2023-08-09 Trend Power changed from almost flat to medium strength.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from to almost flat.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.


Current temperature: 0.42
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 27.20
Mean unverified/preliminary 27.20 / 27.20
Target Price Low / High 25.60 / 30.00
Median / STD DEV 26.00 / 2.18
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi Sell None Sell
macd None None None
stoch None None None
ma20 Sell Sell Sell
ma50 None None None
ma100 None Sell None
Candlestick PatternJune 7, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US24344T1016
ceo Mr. Steven L. Hoerter
Website https://www.deciphera.com
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.